Showing 2941-2950 of 4165 results for "".
- FDA Approves Juvederm Voluma XC for Temple Hollowinghttps://modernaesthetics.com/news/fda-approves-juvederm-voluma-xc-for-temple-hollowing/2473553/Allergan Aesthetics has received FDA approval of Juvederm Voluma XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.[1] The injection is the first and only hyaluronic acid (HA) dermal filler to receive FDA approval
- Cutera Launches AviClear for the Treatment of Acne in UK, Europe and Australiahttps://modernaesthetics.com/news/cutera-launches-aviclear-for-the-treatment-of-acne-in-uk-europe-and-australia/2473548/Cutera announced the international limited commercial release of AviClear, which the company describes as the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. AviClear is now commercially available, on a limited basis, in the UK, Europe, a
- Demand Up, Fees Downhttps://modernaesthetics.com/news/demand-up-fees-down/2473541/The latest study from The American Society of Plas
- Genese Labs Introduces the RG60 Body Fillerhttps://modernaesthetics.com/news/genese-labs-introduces-the-rg60-body-filler/2473539/Genese Labs France is rolling out the RG60 Body Filler, an injectable composed of a 24mg/ml cross-linked hyaluronic acid concentration. RG60 can be used in the face and body including the buttocks. Free from lidocaine, RG60 ensures a safer experience
- Allergan Aesthetics and The Black Beauty Club Partner to Foster Diversity in Aestheticshttps://modernaesthetics.com/news/allergan-aesthetics-x-the-black-beauty-club-partner-to-advance-diversity-in-aesthetics/2473531/Allergan Aesthetics joined forces with the Black Beauty Club for a consumer initiative to spark open dialogue and empower Black individuals to embrace their unique beauty and make informed decisions about their aesthetic care. The event, which took place in Atlanta on Novembe
- Exosome Update: ELEVAI Labs Announces Pricing of $6,000,000 IPOhttps://modernaesthetics.com/news/exosome-update-elevai-labs-announces-pricing-of-6000000-ipo/2473530/Elevai Labs, Inc. announced the pricing of its initial public offering. The Offering consists of 1,500,000 shares of common stock at a public offering price of $4.00 per share, for total gross proceeds of $6,000,000 before deducting underwriting discounts and o
- Natrelle Unveils New "For Every BODY" Campaignhttps://modernaesthetics.com/news/natrelle-unveils-new-for-every-body-campaign/2473519/Allergan Aesthetics’ is launching "For Every BODY," a new Natrelle campaign that showcases how the Natrelle breast implant portfolio can provide a customized look for every body. "Our mar
- RelabotulinumtoxinA Update from Galdermahttps://modernaesthetics.com/news/relabotulinumtoxina-update-from-galderma/2473504/The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Galderma related to its pending Biologics License Application (BLA) for RelabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity
- Merz Aesthetics’ Belotero Balance (+) Receives FDA Approval for Infraorbital Hollowshttps://modernaesthetics.com/news/merz-aesthetics-belotero-balance-receives-fda-approval-for-infraorbital-hollows/2473500/The U.S. Food and Drug Administration (FDA) approved Merz Aesthetics’ Belotero Balance (+) for improvement of the infraorbital hollow (IOH) in adults over the age of 21. This approval stems from positive pivotal study results demonstrating the efficacy and safety of Belotero
- Will Platysma Prominence Be the Next Nod for BOTOX Cosmetic?https://modernaesthetics.com/news/will-platysma-prominence-be-the-next-nod-for-botox-cosmetic/2473497/Allergan Aesthetics’ BOTOX Cosmetic met all primary and secondary endpoints for the treatment of moderate to severe platysma prominence associated with platysma muscle activity, according to topline results from the second of three Phase 3 studies. The multicenter, randomized